Breaking News Instant updates and real-time market news.

BAC

Bank of America

$16.13

-0.09 (-0.55%)

, DAL

Delta Air Lines

$38.95

-0.99 (-2.48%)

07:35
10/10/16
10/10
07:35
10/10/16
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in Bank of America (BAC), Delta (DAL), Merck (MRK), Yum! Brands (YUM), Juniper Networks (JNPR), CBI (CBI), Rio Tinto (RIO), and Realogy Holdings (RLGY).

BAC

Bank of America

$16.13

-0.09 (-0.55%)

DAL

Delta Air Lines

$38.95

-0.99 (-2.48%)

MRK

Merck

$62.77

0.11 (0.18%)

YUM

Yum! Brands

$87.72

0.28 (0.32%)

JNPR

Juniper

$24.81

0.29 (1.18%)

CBI

CB&I

$28.74

-0.1 (-0.35%)

RIO

Rio Tinto

$33.16

-0.02 (-0.06%)

RLGY

Realogy

$25.72

-0.49 (-1.87%)

  • 11

    Oct

  • 13

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 17

    Nov

  • 08

    Dec

BAC Bank of America
$16.13

-0.09 (-0.55%)

09/13/16
SOCG
09/13/16
DOWNGRADE
SOCG
Hold
Bank of America downgraded to Hold from Buy at Societe Generale
09/16/16
GSCO
09/16/16
NO CHANGE
Target $19
GSCO
Conviction Sell
Bank of America operating leverage hitting an inflection, says Goldman
Goldman analyst Richard Ramsden believes Bank of America is hitting an inflection point in operating leverage driven by low single digit growth, stable credit, and absolute reductions in the expense base. The analyst believes topline growth will reach approximately 4% annually through to 2018, driven by consumer bank and wealth management initiatives. Ramsden reiterates his Conviction Buy rating on Bank of American and raised his price target to $19 from $17 given the combination of revenue growth and expense discipline.
09/13/16
SOCG
09/13/16
DOWNGRADE
Target $42
SOCG
Sell
Societe Generale cuts Citi to Sell, Bank of America to Hold
Societe Generale downgraded Citi (C) to Sell from Hold and Bank of America (BAC) to Hold from Buy. The firm has a $42 price target for shares of Citi and attributes an increased negative stance on Cards for the downgrade. Societe Generale has a $17 price target for Bank of America and cites revenue growth for the downgrade to Hold. Citi is trading down 86c to $46.93 and Bank of America is trading down 19c to $15.71.
10/10/16
OPCO
10/10/16
NO CHANGE
OPCO
Oppenheimer technical analyst upgrades Financials, downgrades Consumer Staples
Oppenheimer technical analyst Ari Wald upgraded the Financials sector to Market Weight and downgraded Consumer Staples to Underweight in next step in the firm's "cyclical rotation road map." Wald identified Ameriprise (AMP), Bank of America (BAC), Citi (C), Goldman Sachs (GS), Lincoln National (LNC) and SunTrust (STI) as six stocks breaking higher that he sees as likely to benefit from internal market rotation.
DAL Delta Air Lines
$38.95

-0.99 (-2.48%)

07/15/16
EVER
07/15/16
DOWNGRADE
EVER
Hold
Delta Air Lines downgraded to Hold from Buy at Evercore ISI
Evercore ISI analyst Duane Pfennigwerth downgraded Delta Air Lines to Hold with a $50 price target. The analyst said Delta's Q2 earnings were ahead but preliminary unit revenue guidance of down 4-6% implies no sequential improvement at midpoint despite 1 % point slower capacity growth. Pfennigwerth said revenue trends during the peak summer demand period are weaker and he would like to see evidence that corporate revenue trends have stabilized before becoming constructive on shares.
07/14/16
RAJA
07/14/16
NO CHANGE
RAJA
Outperform
Delta Air Lines Q3 passenger unit revenue to pressure shares, says Raymond James
Raymond James analyst Savanthi Syth said Delta's Q2 came in slightly ahead of consensus but shares will likely be pressured on the Q3 passenger unit revenue outlook. The analyst said delta moderated Q4 capacity growth with winter cuts in the US-UK market, which should be viewed as a positive. Syth rates Delta an Outperform.
08/24/16
IMPC
08/24/16
INITIATION
Target $41
IMPC
In-Line
Delta Air Lines initiated with an In-Line at Imperial Capital
Imperial Capital analyst Michael Derchin initiated Delta Air Lines with an In-Line and $41 price target citing the potential impact on UK business travel from Brexit and deteriorating economic, social and terrorism problems in Europe.
08/24/16
08/24/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lockheed Martin (LMT) reinstated with a Neutral at Goldman. 2. Five Below (FIVE) initiated with a Neutral at BTIG. 3. AMC Entertainment (AMC) and Cinemark (CNK) were initiated with a Buy at Loop Capital while the firm initiated Regal Entertainment (RGC) with a Hold. 4. Delta Air Lines (DAL) initiated with an In-Line at Imperial Capital. 5. LINE Corp. (LN) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, Reference Link
MRK Merck
$62.77

0.11 (0.18%)

09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
YUM Yum! Brands
$87.72

0.28 (0.32%)

09/29/16
OPCO
09/29/16
NO CHANGE
Target $97
OPCO
Outperform
Yum! Brands remains a favorite at Oppenheimer
Oppenheimer analyst Brian Bittner says Yum! Brands remains one of his "favorite Outperforms," despite its 23% year-to-date gain. The analyst raised his price target on the stock to $97 from $96, citing his updated sum-of-parts heading into the October 31 separation of the company's China business. Nonetheless, Bittner notes that this does not incorporate additional potential upside from an attractive G&A opportunity, potential for larger than expected capital returns post-separation at both entities, and continued earnings power restoration at Yum China. He reiterates an Outperform rating on the shares.
09/23/16
09/23/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from Sector Perform by RBC analyst Mark Mahaney, who cut his price target to $14 from $17. The research firm's survey of more than 1,100 advertising professionals and their attitudes towards Facebook (FB), Google (GOOG), Twitter and other high-profile names showed that, despite marketing budgets continuing to shift online, interest in the microblog platform appears to be declining. Of note, Twitter shares have surged this morning after CNBC's David Faber reported that Twitter is moving closer to selling itself and has received expressions of interest in a possible sale, although no deal is imminent. 2. Yum! Brands (YUM) downgraded to Outperform from Top Pick by RBC Capital analyst David Palmer based on valuation. His price target on Yum shares remains $97. 3. Becton Dickinson (BDX) downgraded to Sell from Neutral by Citi analyst Amit Hazan, who thinks a cyclical U.S. slowdown will push the company's organic growth below expectations. The analyst, who also sees a diminishing impact on Becton's growth from emerging markets, cut his price target for the shares to $165 from $167. 4. NextEra Energy (NEE) downgraded to Hold from Buy by Deutsche Bank analyst Jonathan Arnold, as he sees limited near-term upside with the shares up 23% year-to-date. "Extraordinarily frosty commentary" from two of three PUCT commissioners yesterday regarding NextEra's Oncor deal indicates an uphill battle in getting it approved, Arnold tells investors. 5. AVANGRID (AGR) downgraded to Underweight from Neutral by JPMorgan analyst Christopher Turnure, who thinks both the company's growth guidance and consensus expectations "appear ambitious." He lowered his price target for the shares to $41 and $44 and notes he does not have confidence in AVANGRID's near-term growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
OPCO
10/06/16
NO CHANGE
Target $97
OPCO
Outperform
Oppenheimer would be aggressive buyer of Yum! Brands below $90
After Yum! Brands reported an in-line earnings quarter, Oppenheimer analyst Brian Bittner remains attracted to the shares ahead of several catalysts. The analyst would be an aggressive buyer of Yum! Brands below $90 per share. He reiterates an Outperform rating and $97 price target on the stock.
09/29/16
BERN
09/29/16
NO CHANGE
BERN
New Yum! poised to benefit from cost cutting, unit growth, says Bernstein
Bernstein analyst Sara Senatore says that New Yum! - the global franchisor of KFC, Pizza Hut, and Taco Bell which will trade separately from the current company's China assets following an upcoming spin off - should benefit from cost cutting and steady unit growth. New Yum! will be able to cut up to $140M+.of costs, and "steady unit growth" should "provide underlying support" for its revenue, she stated. The analyst keeps a $98 price target and Outperform rating on current, combined Yum!.
JNPR Juniper
$24.81

0.29 (1.18%)

06/22/16
JMPS
06/22/16
NO CHANGE
JMPS
Activist investor could persuade Imperva to sell itself, says JMP Securities
After activist investor Elliott acquired a 10% stake in Imperva (IMPV), JMP Securities thinks that Elliott will persuade the company to consider strategic alternatives and could convince the company to look to sell itself.. The firm believes that the company is "a strong acquisition prospect" for large companies such as HP (HPE), Cisco (CSCO), Juniper (JNPR), and Symantec (SYMC). The firm believes that Elliott will improve the company's cost management and execution. It reiterates a $57 price target and Outperform rating on Imperva.
07/01/16
OTRG
07/01/16
NO CHANGE
OTRG
Juniper's Q2 enterprise business stabilized, says OTR Global
OTR Global said Juniper's enterprise business stabilized during Q2, following the SAP implementation in January, and sales plan and win rate trends slightly quarter-over-quarter despite concerns about backlog.
07/06/16
DBAB
07/06/16
DOWNGRADE
Target $22
DBAB
Hold
Juniper downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath downgraded Juniper Networks to Hold saying his firm's Service Provider Channel research indicated the potential for margin pressure and share loss in the company's Routing business in FY17 and FY18. The analyst cut his price target for Juniper shares to $22 from $30.
07/20/16
PIPR
07/20/16
NO CHANGE
PIPR
Piper survey shows networking infrastructure demand slowed meaningfully
Piper Jaffray analyst Troy Jensen says his firm's Q2 Networking survey, which consisted of 36 resellers/distributors located in the U.S. and Europe, indicated that demand for networking infrastructure saw a meaningful slowdown in the June quarter. The survey indicated demand was weak across most vendors, with "some of the worst results in recent memory" from Cisco (CSCO), Juniper (JNPR) and F5 Networks (FFIV), Jensen tells investors in a research note. The analyst recommends caution on the space heading into the Q2 earnings season.
CBI CB&I
$28.74

-0.1 (-0.35%)

07/26/16
SBSH
07/26/16
NO CHANGE
SBSH
Citi removes CB&I from Recommended List, adds Jacobs
Citi analyst Tobias Levkovich removed CB&I (CBI) from his firm's Recommended List while adding Jacobs Engineering (JEC). The firm yesterday downgraded CB&I to Neutral.
09/21/16
JRCO
09/21/16
DOWNGRADE
JRCO
Hold
CB&I downgraded to Hold from Buy at Johnson Rice
07/22/16
BARD
07/22/16
DOWNGRADE
Target $40
BARD
Neutral
CB&I downgraded to Neutral on litigation concerns at Baird
Baird analyst Andrew Wittmann downgraded CB&I to Neutral from Outperform after litigation was filed this morning between the company and Westinghouse, its former partner for U.S. nuclear projects. The court filing shows a $2.4B difference on working capital adjustments associated with last year's transaction, Wittmann tells investors in a research note. The lawsuit looks "frivolous," but is an overhang nonetheless, the analyst contends. He cut his price target for the shares to $40 from $45. UBS this morning also downgraded CB&I on the Westinghouse overhang. The stock is down 7%, or $2.64, to $36.11 in morning trading.
07/25/16
SBSH
07/25/16
DOWNGRADE
Target $38
SBSH
Neutral
CB&I downgraded to Neutral from Buy at Citi
Citi analyst Andrew Kaplowitz downgraded CB&I to Neutral saying he was disappointed to learn via the company's legal complaint against Westinghouse that it does not have 100% indemnification of any future earnings/cash impact from the "troublesome" new nuclear construction projects. Kaplowitz cut his price target for CB&I shares to $38 from $48. Baird and UBS on Friday morning also downgraded shares of CB&I.
RIO Rio Tinto
$33.16

-0.02 (-0.06%)

09/29/16
CIBC
09/29/16
UPGRADE
CIBC
Sector Performer
Rio Tinto upgraded to Sector Performer from Underperformer at CIBC
09/12/16
JPMS
09/12/16
UPGRADE
JPMS
Overweight
Rio Tinto upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Lyndon Fagan upgraded Rio Tinto (RIO) to Overweight saying his firm's higher near-term iron ore price forecasts improve the company's free cash flow outlook. The analyst views the current valuation as attractive and continues to prefer Rio to BHP Billiton (BHP). He upped his price target for Rio shares to A$54 from A$51.
07/20/16
SOCG
07/20/16
DOWNGRADE
SOCG
Hold
Rio Tinto downgraded to Hold from Buy at Societe Generale
09/08/16
RBCM
09/08/16
UPGRADE
RBCM
Outperform
Rio Tinto upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Tyler Broda upgraded Rio Tinto to Outperform with a price target of GBP 3,400. The analyst believes the company's has attractive growth opportunities and points out the stock has underperformed year-to-date.
RLGY Realogy
$25.72

-0.49 (-1.87%)

07/12/16
SPHN
07/12/16
UPGRADE
Target $37
SPHN
Overweight
Realogy upgraded to Overweight from Equal Weight at Stephens
Stephens analyst John Campbell upgraded Realogy to Overweight from Equal Weight, as he views the stock's valuation as attractive and thinks concerns have been overblown. The analyst keeps a $37 price target on Realogy shares.
10/05/16
WEDB
10/05/16
INITIATION
Target $28.5
WEDB
Neutral
Realogy initiated with a Neutral at Wedbush
Target $28.50.
08/04/16
08/04/16
NO CHANGE

Realogy sees FY16 adjusted EBITDA $845M-$885M
Sees Adjusted EBITDA margin of 14.7% to 15.0%. Realogy expects to convert approximately 60% of its forecasted Operating EBITDA, expected to be $760M-$800M, into free cash flow ranging between $450M-$500M.
07/25/16
KBWI
07/25/16
UPGRADE
Target $36
KBWI
Outperform
Realogy upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Bose George upgraded Realogy to Outperform with a $36 price target citing valuation.

TODAY'S FREE FLY STORIES

DGX

Quest Diagnostics

$110.14

0.44 (0.40%)

, WMT

Wal-Mart

$75.59

0.75 (1.00%)

15:12
06/26/17
06/26
15:12
06/26/17
15:12
Recommendations
Quest Diagnostics, Wal-Mart analyst commentary  »

Raymond James positive on…

DGX

Quest Diagnostics

$110.14

0.44 (0.40%)

WMT

Wal-Mart

$75.59

0.75 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

NOV

National Oilwell

$31.84

0.2 (0.63%)

15:10
06/26/17
06/26
15:10
06/26/17
15:10
Options
Notable call writing in National Oilwell »

Notable call writing in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

VTR

Ventas

$71.94

0.215 (0.30%)

15:07
06/26/17
06/26
15:07
06/26/17
15:07
Conference/Events
Ventas management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MU

Micron

$32.50

0.765 (2.41%)

15:05
06/26/17
06/26
15:05
06/26/17
15:05
Options
Micron call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 29

    Aug

MAR

Marriott

$104.06

0.17 (0.16%)

15:00
06/26/17
06/26
15:00
06/26/17
15:00
Conference/Events
Marriott management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.92

1.38 (14.47%)

14:54
06/26/17
06/26
14:54
06/26/17
14:54
Periodicals
Apple only leasing six cars from Hertz, CNBC says »

After Bloomberg reported…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.92

1.38 (14.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NG

NovaGold

$4.50

-0.075 (-1.64%)

14:49
06/26/17
06/26
14:49
06/26/17
14:49
Options
NovaGold options imply 6.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.84

1.3002 (13.63%)

14:47
06/26/17
06/26
14:47
06/26/17
14:47
Periodicals
Hertz to manage small self-driving car fleet for Apple, Bloomberg says »

Apple (AAPL) is leasing a…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.84

1.3002 (13.63%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

CAR

Avis Budget

$24.24

1.23 (5.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

OTIC

Otonomy

$18.75

1 (5.63%)

14:46
06/26/17
06/26
14:46
06/26/17
14:46
Conference/Events
Otonomy to hold a breakfast meeting »

Chief Scientific Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

, WMT

Wal-Mart

$75.61

0.77 (1.03%)

14:44
06/26/17
06/26
14:44
06/26/17
14:44
Hot Stocks
Quest Diagnostics, Wal-Mart team up to offer healthcare services »

Quest Diagnostics (DGX)…

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

WMT

Wal-Mart

$75.61

0.77 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

EBSB

Meridian Bancorp

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Upgrade
Meridian Bancorp rating change  »

Meridian Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$14.17

-0.21 (-1.46%)

, INTC

Intel

$34.19

-0.17 (-0.49%)

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Recommendations
AMD, Intel analyst commentary  »

Goldman reiterates Sell…

AMD

AMD

$14.17

-0.21 (-1.46%)

INTC

Intel

$34.19

-0.17 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Aug

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

, PRXL

Parexel

$86.80

-0.31 (-0.36%)

14:41
06/26/17
06/26
14:41
06/26/17
14:41
Hot Stocks
Kitov sees formal filing of NDA for KIT-302 by end of Q3 »

Kitov Pharmaceuticals…

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

PRXL

Parexel

$86.80

-0.31 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

RAD

Rite Aid

$3.93

0.8199 (26.36%)

14:40
06/26/17
06/26
14:40
06/26/17
14:40
Options
Heavy trading in RiteAid as shares surge »

Heavy trading in RiteAid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:40
06/26/17
06/26
14:40
06/26/17
14:40
General news
Treasury Action: yields remain slightly lower »

Treasury Action: yields…

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:39
06/26/17
06/26
14:39
06/26/17
14:39
Conference/Events
EVINE Live management to meet with Craig-Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:38
06/26/17
06/26
14:38
06/26/17
14:38
Conference/Events
EVINE Live management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

HTZ

Hertz

$10.19

0.65 (6.81%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Technical Analysis
Technical View: Hertz spikes higher, levels to watch »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAG

AMAG Pharmaceuticals

$18.35

0.15 (0.82%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Recommendations
AMAG Pharmaceuticals analyst commentary  »

AMAG delay for Makena…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$45.60

5.58 (13.94%)

14:30
06/26/17
06/26
14:30
06/26/17
14:30
Options
Timely call activity in Fabrinet »

Timely call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 29

    Aug

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.24

0.7 (7.34%)

14:26
06/26/17
06/26
14:26
06/26/17
14:26
Periodicals
Breaking Periodicals news story on Apple, Hertz »

Hertz to manage small…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.24

0.7 (7.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GM

General Motors

$34.49

0.29 (0.85%)

14:25
06/26/17
06/26
14:25
06/26/17
14:25
Conference/Events
General Motors to host a conference call »

EVP & CFO Chuck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

T

AT&T

$38.15

0.2001 (0.53%)

14:20
06/26/17
06/26
14:20
06/26/17
14:20
Options
Calendar call spread in AT&T rolls short position from July to September »

Calendar call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:19
06/26/17
06/26
14:19
06/26/17
14:19
General news
Averages mixed but internals strong »

The averages remain mixed…

$NSD

NASDAQ Market Internals

14:17
06/26/17
06/26
14:17
06/26/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.